Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Daclizumab (anti-CD25) in multiple sclerosis.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Laquinimod
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Puma, but not noxa is essential for oligodendroglial cell death.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.

Pages